0 Reacties
0 aandelen
4 Views
0 voorbeeld
Zoeken
Ontdek nieuwe mensen, nieuwe verbindingen te maken en nieuwe vrienden maken
-
Please log in to like, share and comment!
-
Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease testsRoth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...0 Reacties 0 aandelen 6 Views 0 voorbeeld